BeOne Medicines AG (ONC)
NASDAQ: ONC · Real-Time Price · USD
322.90
-8.50 (-2.56%)
At close: Dec 5, 2025, 4:00 PM EST
322.40
-0.50 (-0.15%)
After-hours: Dec 5, 2025, 7:07 PM EST
BeOne Medicines AG Stock Forecast
Stock Price Forecast
The 12 analysts with 12-month price forecasts for BeOne Medicines AG stock have an average target of 369.5, with a low estimate of 312 and a high estimate of 408. The average target predicts an increase of 14.43% from the current stock price of 322.90.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for BeOne Medicines AG stock from 12 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jun '25 | Jul '25 | Aug '25 | Sep '25 | Oct '25 | Nov '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 4 |
| Buy | 7 | 7 | 7 | 8 | 8 | 8 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 9 | 9 | 9 | 10 | 10 | 12 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Truist Securities | Truist Securities | Strong Buy Initiates $400 | Strong Buy | Initiates | $400 | +23.88% | Nov 24, 2025 |
| RBC Capital | RBC Capital | Buy Maintains $395 → $408 | Buy | Maintains | $395 → $408 | +26.35% | Nov 18, 2025 |
| Citigroup | Citigroup | Strong Buy Maintains $399 → $405 | Strong Buy | Maintains | $399 → $405 | +25.43% | Nov 10, 2025 |
| RBC Capital | RBC Capital | Buy Maintains $374 → $395 | Buy | Maintains | $374 → $395 | +22.33% | Nov 7, 2025 |
| Citizens | Citizens | Buy Maintains $348 → $396 | Buy | Maintains | $348 → $396 | +22.64% | Nov 7, 2025 |
Financial Forecast
Revenue This Year
37.93B
from 27.81B
Increased by 36.37%
Revenue Next Year
46.29B
from 37.93B
Increased by 22.04%
EPS This Year
1.42
from -44.70
EPS Next Year
3.34
from 1.42
Increased by 134.77%
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 40.3B | 49.9B | ||||
| Avg | 37.9B | 46.3B | ||||
| Low | 36.2B | 43.5B |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 44.8% | 31.5% | ||||
| Avg | 36.4% | 22.0% | ||||
| Low | 30.1% | 14.8% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 2.15 | 4.40 | ||||
| Avg | 1.42 | 3.34 | ||||
| Low | 0.49 | 2.30 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | 209.3% | ||||
| Avg | - | 134.8% | ||||
| Low | - | 62.1% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.